burosumab
Generic: burosumab·Brand: Crysvita
burosumab: developed by 1 company · 1 clinical trial tracked.
burosumab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect burosumab to RARE; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could burosumab → RARE affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalac… | Approved |
Clinical Trials (1)
An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
Primary endpoint: Serum Phosphorus change
Interventionalopen1 enrolledStarted 2019-07Completion 2026-031 site · United StatesLaura Tosi
Frequently asked questions
Who is developing burosumab?
burosumab is being developed by Ultragenyx Pharmaceutical Inc..
How many clinical trials involve burosumab?
BioSniper tracks 1 clinical trial involving burosumab.